About the journal
Hepatic Oncology is an open-access journal published by Taylor & Francis in United Kingdom, publishing in english. It is listed in DOAJ and PUBMED according to the sources read. Declared publication charge: 2,195 USD. Declared review time at DOAJ: 13 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Taylor & Francis
- ISSN
- 2045-0923 · 2045-0931
- Country
- United Kingdom
- Languages
- english
- Access
- Open access
- Declared publication charge
- 2,195 USD
- Articles in DOAJ
- 66
- Declared review time
- 13 weeks
- Declared peer-review model
- double_blind
- Official website
- https://www.tandfonline.com/journals/ihep20
Index listings
- DOAJ · 2019-03-11
- PUBMED · 2014-01-01
- Indexing
- DOAJ · PUBMED
- APC
- 2,195 USD
- Declared review time (DOAJ)
- 13 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
66
Most recent article
4 months ago
Average review time (journal-declared via DOAJ)
13weeks
Works in OpenAlex
208
Last recorded publication year
2025
h-index
26
i10-index
68
From OpenAlex open data (CC0).
Editorial & policy13
- Last DOAJ review date
- 2024-08-13
- Added to DOAJ
- 2019-03-11
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSLOCKSSPMC
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 100%
- ORCID iDs in current deposits
- 63%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101629607
Classification4
Subjects (DOAJ)
LCC codes
Subject areas
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver physiology and pathology
- Liver physiology and pathology
Show all subjects (50)
- Cancer Mechanisms and Therapy
- Cancer Mechanisms and Therapy
- Hepatitis B Virus Studies
- Hepatitis B Virus Studies
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Gallbladder and Bile Duct Disorders
- Liver Disease and Transplantation
- Liver Disease and Transplantation
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Organ Transplantation Techniques and Outcomes
- Organ Transplantation Techniques and Outcomes
- Hepatitis C virus research
- Hepatitis C virus research
- Cancer, Lipids, and Metabolism
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Pediatric Hepatobiliary Diseases and Treatments
- Pediatric Hepatobiliary Diseases and Treatments
- RNA modifications and cancer
- Renal cell carcinoma treatment
- PI3K/AKT/mTOR signaling in cancer
- Cancer Research and Treatment
- Alcohol Consumption and Health Effects
- Renal cell carcinoma treatment
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Epigenetics and DNA Methylation
- Lung Cancer Treatments and Mutations
- MicroRNA in disease regulation
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- Viral-associated cancers and disorders
Keywords (DOAJ)
- hepatic oncology
- liver cancer
- liver tumours
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ